Veloxis Pharmaceuticals A/S provided earnings guidance for the full year 2019. For the year, the company maintains its 2019 guidance of revenues to be in the range of USD 58 million to USD 68 million and operating income before accounting for stock compensation in the range of USD 4 million to USD 10 million.